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Introduction
In June 2003, an international group
of scientists proposed the creation of a
Global HIV Vaccine Enterprise [1]. The
authors invited discussion of this pro-
posal, and challenged scientists to
identify new strategies and mechanisms
to accelerate the global effort to devel-
opasafeandeffective HIVvaccine.This
paperdescribestheprocessesthatledto
agreement on the major roadblocks in
HIV vaccine development, summarizes
current scientiﬁc priorities, and de-
scribes an initial strategic approach to
address those priorities. Speciﬁc re-
search is not prescribed. Rather, the
intent is to stimulate both researchers
and funders to explore new, more
collaborative, cooperative, and trans-
parent approaches to address the major
obstacles in HIV vaccine development
identiﬁed in the plan, in addition to
continuing the productive, high-quality
programs already underway.
The motivation behind the proposal
for a Global HIV/AIDS Vaccine Enter-
prise was the recognition that devel-
opment of an HIV vaccine remains one
of the most difﬁcult challenges con-
fronting biomedical research today
[2,3]. Fortunately, scientiﬁc progress
has created new opportunities that
could be harnessed more effectively
through global coordination and col-
laboration. These new opportunities
include an expanded HIV vaccine
candidate pipeline, improvements in
animal models, a growing database
from clinical trials, and the availability
of new quantitative laboratory tools
that make comparisons among vaccine
studies feasible. Confronting major
roadblocks and harnessing these new
opportunities requires an effort of a
magnitude, intensity, and design with-
out precedent in biomedical research,
with the Human Genome Project as a
potentially useful model [4]. More
speciﬁcally, the critical scientiﬁc in-
sights generated by the creativity of
individual investigators, as well as small
groups and individual networks, could
be signiﬁcantly augmented by a prop-
erly organized, managed, and system-
atized international effort targeted on
the design and clinical evaluation of
novel HIV immunogens. An interna-
tional collaborative effort that ad-
dresses a shared scientiﬁc plan,
provides information exchange among
groups, links clinical trials with stand-
ardized laboratory assays and evalua-
tion in animal models, applies new
knowledge to improvements in vaccine
design in an iterative manner, and
supports a transparent process for
decision making in all aspects of
vaccine discovery, design, development,
and clinical testing will prove critical to
success.
The Global HIV/AIDS Vaccine En-
terprise represents a novel paradigm to
seek and identify international agree-
ment on the critical roadblocks for
developing an HIV vaccine and on
creating a shared scientiﬁc plan that
addresses those roadblocks (see Box 1).
The Enterprise proposes to coordinate
efforts at a global level, facilitate use of
common tools and technologies, and
help ensure access to optimized re-
sources. Furthermore, the Enterprise
approach is a way of behaving as a
global community of problem-solvers,
more openly sharing information, en-
suring that the shared scientiﬁc plan is
implemented, and basing decisions on
evidence rather than advocacy.
It must be emphasized, however, that
the major difﬁculties encountered in
the development of an HIV vaccine are
scientiﬁc, not organizational, and arise
directly from the complexities of HIV
and AIDS. ‘‘Small science’’ should not
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approaches must be undertaken. Crea-
tion of research environments that
support the creativity both of individ-
ual investigators and of larger, collab-
orative efforts will accelerate the
scientiﬁc breakthroughs needed to
successfully develop a safe and effective
HIV vaccine.
Scientific Priorities
Prioritization process. In August
2003, the authors of the Enterprise
proposal invited a group of leading
scientists, public health experts, and
policy makers to meet at the Airlie
House in Warrenton, Virginia, United
States, to reﬁne the vision for the
Enterprise. The Airlie group agreed
that the Global HIV/AIDS Vaccine
Enterprise should be developed as an
alliance of independent organizations
committed to accelerating the devel-
opment of a preventive vaccine for
HIV/AIDS through implementation of
a shared scientiﬁc strategic plan, mo-
bilization of additional resources, and
greater collaboration among HIV vac-
cine researchers worldwide [5].
The subsequent initial planning
phase of the Enterprise involved lead-
ing government research agencies, pri-
vate industry, non-governmental
organizations, and funders involved in
HIV vaccine research and development
(R&D) activities, including the Bill &
Melinda Gates Foundation (BMGF), the
International AIDS Vaccine Initiative
(IAVI), the National Agency for Re-
search on AIDS of France (ANRS), the
United States National Institutes of
Health (NIH), the United Nations Joint
Programme on HIV/AIDS (UNAIDS),
the World Health Organization (WHO),
and the Wellcome Trust. The Enter-
prise is expected to grow with time and
include additional organizations and
research groups willing to contribute
to the implementation of its scientiﬁc
strategic plan. A Steering Committee
composed of representatives from sev-
eral of the founding organizations
provided guidance and coordination,
with the BMGF serving as interim
Secretariat.
Six Working Groups involving more
than 120 participants from 15 coun-
tries, the WHO, and UNAIDS were
formed to develop the scientiﬁc plan of
the Enterprise. These Working Groups
met from January to April 2004, iden-
tiﬁed critical unanswered questions,
and proposed actions to address them.
In May 2004, the Steering Committee
of the Enterprise analyzed the recom-
mendations from the Working Groups
and identiﬁed the scientiﬁc priorities
for initial action.
Several common themes emerged
from the Working Groups. There was
clear agreement on the key scientiﬁc
challenges, as well as strong consensus
that the HIV vaccine ﬁeld has pro-
gressed to a point where it should be
possible to answer some of the persis-
tent questions more deﬁnitively. To
meet these challenges, the Working
Groups called for enhanced access to
reagents and technologies, adequate
resources, and strengthened human
capacity in several key areas, especially
in developing countries, where clinical
trials need to be conducted. There was
also agreement that the present way of
doing business, which centers primarily
on individually led research groups or
networks, needs to be supplemented by
establishing focused, collaborative
structures and providing access to
common standards and technologies,
which would enable comparison of data
and candidate vaccines. This would, in
turn, support a rational process for
decision making to advance candidate
vaccines through the different phases
of evaluation.
Vaccine discovery. One immediate
goal is to design HIV candidate vac-
cines that consistently induce potent,
broadly reactive, persistent neutraliz-
ing antibodies, as well as memory T
cells that suppress viral replication and
prevent escape of virus from immune
control [6,7]. Additional research is also
needed to identify how mucosal [8] and
innate [9,10] immunity could be har-
nessed to develop effective HIV vac-
cines. The ability to develop effective
vaccines would be greatly enhanced by
an understanding of what speciﬁc
immune response or responses corre-
late with vaccine-induced protection
[11].
The current state of the art suggests a
two-pronged strategy to accelerate the
development of a safe and effective
HIV vaccine. One component should
center on candidate vaccines already in
the pipeline, nearly all of which are
designed primarily to induce T cell
responses. In some animal models these
T-cell-inducing candidate vaccines
suppress post-infection viremia and
Box 1. Key Points in the
Scientific Strategic Plan
  More new HIV infections and AIDS
deaths occurred in 2004 than in any prior
year (Figures 1–3). A vaccine is critical for
the control of the pandemic.
  Development of an HIV vaccine is one of
the world’s most difficult and important
biomedical challenges.
  Harnessing new scientific opportunities
for HIV vaccine development will require
an effort of a magnitude, intensity, and
design without precedent in biomedical
research.
  The Global HIV Vaccine Enterprise is an
alliance of independent organizations
committed to accelerating the develop-
ment of a preventive HIV/AIDS vaccine
based on a shared scientific plan.
  The scientific strategic plan was devel-
oped with the collaboration of over 140
scientists and other participants from 17
countries and several international organ-
izations.
  The plan identifies critical unanswered
scientific questions along the critical path
for vaccine discovery, from antigen design
to the conduct of clinical trials.
  Novel vaccine candidates need to be
designed to induce high levels of broadly
reactive and persistent immune responses
against HIV strains circulating in different
parts of the world.
  Standardization and validation of high-
throughput laboratory assays conducted
under GLP will allow comparison of results
from different vaccines, which is a linchpin
of rational decision making in vaccine
development.
  The Enterprise will encourage decision
makers to establish clear and transparent
processes to identify and prioritize the
most promising vaccine candidates.
  The Enterprise will seek to engage the
best researchers who are willing to work in
a highly collaborative manner and to
dedicate the majority of their efforts to
solve the fundamental roadblocks in HIV
vaccine development.
  To mount an accelerated global search
for a safe and effective HIV/AIDS vaccine,
annual funding for such research should
double—to US$1.2 billion per year.
  Several founding partners of the Enter-
prise have already committed, or are
planning to commit, new funding to
support the proposed Enterprise activities,
and to create a culture of mutual ac-
countability for the effective implementa-
tion of the scientific strategic plan.
  Enterprise activities are guided by an
international Coordinating Committee,
supported by different technical expert
groups, including representatives from
funders and implementers of HIV vaccine
R&D.
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than prevent infection [12,13]. In stud-
ies of individuals infected with HIV,
viral load correlates with efﬁciency of
transmission [14], suggesting that a
vaccine capable of suppressing viral
load might reduce HIV transmission.
The second component should ad-
dress critical gaps in scientiﬁc knowl-
edge through carefully designed,
focused, coordinated, and well-sup-
ported approaches. The fruits of this
work will be a clearer understanding of
what properties are needed for a
successful vaccine and how to design
candidates that incorporate those
properties.
Scientiﬁc areas in which a more
collaborative and organized Enterprise
approach will be beneﬁcial include the
following: vaccine design based on the
characteristics of recently transmitted
viruses, evaluation of immune corre-
lates of protection in animal models,
and design of novel candidates vaccines
that induce neutralizing antibodies and
T cell immune responses.
Vaccine design. Strategically, vaccines
that are designed based on recently
transmitted viruses hold the best hope
of inducing relevant immune responses
against currently circulating strains.
Recent data suggest that the subset of
viral strains that are sexually trans-
mitted has unique genetic and anti-
genic properties, including greater
susceptibility to neutralization than the
bulk of circulating virus [15]. While
such observations require conﬁrma-
tion, newly transmitted viruses are
nonetheless the crucial targets of vac-
cine-induced immunity. Therefore, vi-
rological and immunological
characterization of acute/early HIV
infection should inform the design of
vaccines and also guide the design of
trials capable of determining whether
immunization impacts virus levels and
the course of HIV infection.
To address these issues, a represen-
tative number of virus strains derived
from recently infected individuals rep-
resenting those populations who will
participate in vaccine efﬁcacy trials,
including populations in developing
countries, should be obtained. These
virus isolates should be subjected to a
comprehensive genetic and biologic
characterization, together with an
analysis of host immune responses and
the genetic background of those pop-
ulations participating in the clinical
trials.
This continuous and ongoing effort
will require a multidisciplinary global
approach, linking investigators who are
conducting epidemiological and cohort
studies (to allow for detection of acute/
early infections), laboratory scientists
working on the virology and immunol-
ogy of acute/early infection and on the
genetic characterization of affected
human populations, vaccine designers
and manufacturers, and clinical tria-
lists. In addition, systems for data
management and analysis that will
facilitate the rapid translation of new
information into improved vaccine
designs need to be developed.
Immune correlates. Nonhuman pri-
mate models of AIDS offer opportuni-
ties to evaluate potential correlates of
immune protection. While a particular
immunization strategy that works in
animal models may or may not predict
protection in humans, important in-
sights into potential immunologic me-
diators of protection would result from
such studies. Several experimental vac-
cines induce varying degrees of pro-
tection against simian
immunodeﬁciency virus (SIV) or chi-
meric simian/human immunodeﬁ-
ciency virus in rhesus macaques. In
particular, studies using models in
which a very high level of protection
from acquisition of infection was
achieved are needed, i.e., immunization
with live attenuated SIV and attenu-
ation of SIV infection by short-term
antiretroviral treatment administered
immediately after SIV inoculation
[16,17].
To facilitate this process, assays for
many different immune responses to
SIV and chimeric simian/human im-
munodeﬁciency virus need to be
standardized, validated, and made
available to different research groups.
Likewise, agreements need to be
reached on those monkey challenge
models that most closely resemble HIV
transmission and infection in humans.
Large numbers of animals will be
needed to achieve statistical signiﬁ-
cance for experimental ﬁndings [18],
which in turn will require expanded
primate breeding and housing capa-
bility. A multidisciplinary approach
that links virologists, immunologists,
vaccine developers, primatologists, da-
ta and project managers, and others
will be needed.
Neutralizing antibodies. There is in-
creasing agreement that a successful
vaccine needs to induce both humoral
and cell-mediated immunity. Develop-
ment of immunogens capable of in-
ducing antibodies that neutralize
primary HIV isolates from all genetic
subtypes and regions of the world
remains the most difﬁcult challenge in
the ﬁeld of HIV vaccinology [19,20].
Success will likely require a deeper
understanding of the structural motifs
of the HIV envelope protein that
interact with cellular receptors and/or
DOI: 10.1371/journal.pmed.0020025.g001
Figure 1. Adults and Children Estimated to Be Living With HIV as of the End of 2004 (Total: 39.4
[35.9–44.3] million)
(Map: UNAIDS/WHO)
Identifying which T cell
candidate vaccine is
most promising has
become an urgent
priority.
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tralizing antibodies [19]. This strategy
will require numerous well-character-
ized, broadly neutralizing monoclonal
antibodies, the application of peptide
and carbohydrate chemistry, structural
biology, and genetic engineering ap-
proaches to immunogen design, and
the use of iterative approaches guided
by the immunogenicity of new designs.
Given the importance of these en-
deavors and the uncertainty as to what
path will lead to success, multiple
intersecting approaches need to be
explored, including, for example, the
design, production, and evaluation of
(1) envelope proteins that stably reveal
neutralization epitopes that may be
only transiently exposed during viral
entry into target cells, (2) immunogens
that contain rigid, stable epitopes that
mimic the portion or portions of
envelope recognized by broadly neu-
tralizing monoclonal antibodies, (3)
modiﬁed envelope proteins that better
expose existing relevant epitopes, and
(4) molecules that resemble a stabilized
version of the mature envelope trimer
on the virion surface. These are exam-
ples of current approaches being ex-
plored, some or all of which may prove
ineffective. Additional novel ideas need
to be proposed and explored.
To achieve the above objectives, new
tools and technologies such as those
able to detect rare, broadly neutralizing
monoclonal antibodies through large-
scale screening of human sera will have
to be developed. In addition, the very
limited existing capacity to translate
structural information into stable im-
munogen products needs to be ex-
panded.
T cell vaccines. Nearly all current
vaccine candidates in the clinical
pipeline are T-cell-inducing vaccines,
e.g., poxvirus recombinant vectors,
adenoviral vectors, DNA constructs
with or without adjuvants, and lip-
opeptides. The ongoing effort to eval-
uate these products and to develop new
ones is considerable [21]. Identifying
which T cell candidate vaccine or
vaccines are most promising has be-
come an urgent priority. However,
these evaluations are being conducted
within separate preclinical research
groups and, to a lesser extent, separate
clinical trial networks, with the result
that candidate vaccines may not be
optimally compared preclinically or
clinically. This approach may result in
delays in identifying the most promis-
ing candidates, and it risks devoting
time and resources to inferior prod-
ucts, although it is recognized that the
speciﬁc immune responses needed for
a successful vaccine remain unknown.
The identiﬁcation and optimization
of promising candidates will require (1)
deﬁning clear, transparent processes
for decision making, (2) establishing
agreement on vaccine characteristics
upon which decisions should be based,
(3) developing and using validated
assays to assess those parameters, to
allow for preclinical and clinical com-
parison among candidates, and (4)
establishing closer coordination and
data-sharing among product develop-
ers, which will accelerate the availabil-
ity of critical information needed to
identify and further develop the most
promising candidates.
Research is also needed to develop
improved novel T-cell-inducing candi-
date vaccines, especially those that
avoid or otherwise circumvent anti-
vector immune responses [22], and
those that induce persisting high levels
of immunity, especially mucosal im-
munity. In addition, a thorough, sys-
tematic exploration of adjuvants that
markedly enhance the quantity, quality,
and durability of immune responses to
HIV vaccines is needed.
Laboratory standardization. Com-
parison of results from preclinical and
clinical studies is the linchpin of
rational decision making regarding
further development of vaccine candi-
dates. Therefore, the initiation of ap-
proaches that will permit valid
comparisons is crucial.
Progress to standardize and validate
a limited number of T cell assays has
been made within the laboratories of
vaccine developers and within some
partnering research networks. This
approach now needs to be more
broadly applied and extended to the
analysis of neutralizing antibody re-
sponses. A robust infrastructure that
develops, expands, and ensures broad
access to quality assay technologies will
allow valid comparison of data across
trials and networks worldwide.
In order to achieve this goal, the
following are required: (1) a decision-
making process to select a set of robust
assays, standardized and validated
across laboratories, for measuring vac-
cine-induced immune responses in
humans and animals; (2) wide avail-
ability of common reagents (such as
peptides, control sera, and virus pan-
els); (3) capacity for developing novel
assays and reagents of potential value
and for their translation to preclinical
and clinical settings; (4) ‘‘core’’ labora-
tories that run selected assays and serve
as a reference laboratory for satellite
laboratories (clinical and preclinical
work would take place in separate
facilities, and clinical studies would
require Good Laboratory Practices
[GLP] conditions); (5) satellite labora-
tories located at or very near clinical
trial sites to carry out a range of
activities such as processing blood,
storing and shipping specimens, and
conducting basic immunological eval-
uation, and to participate in other
Enterprise-organized activities such as
acute/early infection studies; (6) an
ongoing global quality assurance func-
tion encompassing all participating
core and satellite laboratories and
covering both routine safety as well as
immunologic and virologic assess-
ments; and (7) transfer of research
assays and, when and where feasible,
validated endpoint assays to satellite
labs, including the necessary training
activities.
In addition, new assay development
has failed to keep pace with current
understanding of the biology of the
immune system and recent advances in
technology. A more active program of
applied research and assay develop-
ment is needed to explore new con-
cepts that would advance technical
abilities and provide a better under-
standing of the immune responses
generated by HIV vaccines.
Cellular immunity. Two assays are
currently used for the primary evalua-
tion and enumeration of antigen-spe-
ciﬁc T cells: Interferon-c ELISPOT and
multiparameter ﬂow cytometry. The
ELISPOT assay was initially developed
to measure CD8þ T cell responses.
Several observations in both mice and
Development of an HIV
vaccine remains one of
the most difficult
challenges confronting
biomedical research
today.
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immune responses will likely require
stimulation of both CD4þ and CD8þ T
cell effector and memory functions; it
is unlikely that induction of Interferon-
c-secreting T cells alone correlates with
protective immunity [11]. Therefore,
additional laboratory assays measuring
multiple HIV-speciﬁc cell types as well
as functional capabilities will be
needed to thoroughly evaluate vaccine-
induced immune responses. These as-
says should also permit rapid assess-
ment of the magnitude and breadth of
immune responses, and enumerate the
speciﬁc epitopes that are recognized.
Humoral immunity. Different labora-
tories use different assays to measure
antibodies that neutralize HIV and
related viruses, SIV and chimeric sim-
ian/human immunodeﬁciency virus.
These assays vary technically, but the
most widely accepted assays measure
reduction in virus infectivity in cells
that express the receptors necessary for
virus entry. Assays that offer the great-
est value are those that are validated,
amenable to high throughput, low in
cost, readily transferable, and that can
be performed according to GLP
guidelines.
The ability to measure the magni-
tude and breadth of neutralization
against diverse HIV strains is essential
to evaluating responses generated by
candidate HIV vaccines. Only with
multiple strains of virus can neutrali-
zation breadth be ascertained in a
meaningful way. Standard panels of
HIV strains are in early stages of
development. Expansion or extension
of current standardization and valida-
tion activities, production and provi-
sion of necessary reagents, and access
to quality assurance programs are
needed to ensure worldwide compara-
bility of assay results [23]. The strains of
virus incorporated into a worldwide
panel need to be carefully selected to
reﬂect the current epidemic and
should include early isolates from
individuals at potential vaccine trial
sites [24]. Molecular epidemiological
studies and elucidation of the role of
genetic factors and immune responses
of the host in the transmission of HIV
at the population level will also help
guide vaccine design and evaluation
[25,26]. Another speciﬁc priority is an
assessment of the neutralizing antibody
response generated in the recently
completed Phase III trials of HIV
envelope glycoprotein 120 candidate
vaccines using a global virus panel. The
results would establish a baseline level
of neutralization potency and breadth
that is non-protective, which would be
extremely valuable in reaching in-
formed decisions about advancing fu-
ture antibody-based candidate
vaccines.
A major obstacle to designing a
suitable global virus panel is the pauc-
ity of information on neutralization
serotypes. There is general agreement
that if a reasonably small number of
neutralization serotypes exist, their
identiﬁcation would guide the creation
of an optimal panel of isolates for
neutralizing antibody assays and the
design of polyvalent immunogens.
Although there is some controversy as
to whether HIV-1 neutralization sero-
types exist, the magnitude of beneﬁt
that would result if serotypes were
identiﬁed warrants establishment of a
neutralization serotype discovery pro-
gram that employs the latest technolo-
gies.
Product development and manufac-
turing. Manufacture of vaccine candi-
dates for large clinical trials and to
meet eventual worldwide demand re-
quires the development of processes
for producing consistent, active vac-
cine batches on a large scale. Develop-
ment of these bioprocesses must be
integrated with analytical work (e.g.,
toxicity and stability testing), incorpo-
rate validated assays, and be applicable
to the manufacture of sufﬁcient vac-
cine to meet global needs after licen-
sure. These processes are typically
individually developed as a candidate
vaccine advances from early clinical
testing to late-stage evaluation and
licensure. Worldwide expertise and
capacity for this bioprocess develop-
ment work is already limiting and exists
almost exclusively in the private sector.
As more HIV candidate vaccines enter
the pipeline, current capacity will be
rapidly exhausted.
The initial priority is to identify or
establish one or more dedicated HIV
vaccine bioprocess and analytical de-
velopment groups that bring together
the skill set and capacity to manufac-
ture different promising candidates for
clinical trials. The bioprocess develop-
ment groups would also help train
people and transfer manufacturing
skills in whole or in part to manufac-
turing sites around the world. This
training program would address the
acute shortage of bioprocess experts.
At a later stage, building, acquiring,
or contracting facilities to carry out
bioprocess and analytical work and to
produce several different types of
candidate vaccines should be consid-
ered. Such facilities would further assist
in transferring manufacturing tech-
nology to other production facilities,
preferably in one or more developing
countries. Decisions about which can-
didates a facility undertakes would be
made through a well-deﬁned, compre-
hensive evaluation process. The facili-
DOI: 10.1371/journal.pmed.0020025.g002
Figure 2. Estimated Number of Adults and Children Newly Infected with HIV during 2004 (Total: 4.9
[4.3–6.4] million)
(Map: UNAIDS/WHO)
As more HIV candidate
vaccines enter the
pipeline, current
capacity will be
exhausted.
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provide production capacity to launch
a vaccine for public health use, should
no manufacturer be available to pro-
duce the vaccine quickly upon licen-
sure.
Clinical trials capacity. As a growing
number of HIV candidate vaccines
begin to move through the clinical
trials pipeline, the gap between existing
global capacity and future require-
ments for conducting large efﬁcacy
trials has grown in magnitude and
urgency, especially in developing
countries. This gap in developing
countries must be addressed through
(1) increasing the quantity and quality
of research staff, (2) establishing sus-
tainable research facilities to support
trials, and (3) expanding access to large,
well-deﬁned populations of uninfected
people at high risk of HIV infection.
The recommended solutions take a
long-term view and are aimed at
building site capacity rather than pre-
paring for speciﬁc trials. Sites should
not be conﬁned to conducting HIV
vaccine trials but should be positioned
to contribute to other research of
public health importance to the com-
munity and the country, including, for
example, other areas of HIV research
(e.g., microbicides and treatment) and/
or other diseases. Additional ﬁeld trial
sites must be developed to be able to
conduct planned and anticipated efﬁ-
cacy trials. Sites should be selected in a
strategic, data-driven manner, and
should demonstrate the ability to re-
cruit and retain large numbers of HIV-
negative volunteers from populations
with substantial HIV incidence. New
efﬁcacy trial sites should be developed
in regions with emerging epidemics
rather than only in areas with already-
established disease. ‘‘Early-warning
systems’’ must be available to identify
these newly emerging sub-epidemics.
Deﬁning optimal methods for collec-
tion of HIV incidence data from
populations at potential efﬁcacy trial
sites is essential. Whenever possible,
efﬁcacy trial sites should be linked to
(1) academic medical centers to en-
hance research capacity and help train
clinical researchers, (2) accredited local
and regional laboratory facilities to
provide infection endpoint and safety
assessments, and (3) centers that can
provide appropriate care and treat-
ment to trial participants.
The acute shortage of qualiﬁed per-
sonnel is a major bottleneck to the
conduct of clinical trials in developing
countries with severe or rapidly
emerging HIV epidemics. Development
of intellectual capacity at these sites
should emphasize (1) expanding re-
search training opportunities for per-
sonnel in the broad range of topics
required to conduct high-quality clin-
ical research, (2) establishing and ad-
equately supporting long-term career
paths for such individuals, and (3)
fostering political and social environ-
ments locally and nationally that sup-
port the conduct of clinical research.
Building HIV scientiﬁc and operational
expertise at clinical trial sites should be
linked to other HIV/AIDS research
activities (e.g., identifying and charac-
terizing incident/early HIV infections,
collecting newly transmitted strains,
and measuring incidence in high-risk
populations).
Site development must include
strategies to develop or enhance exist-
ing capacity to deliver health care,
including HIV prevention, care, and
treatment, to the local community
participating in clinical trials. Provi-
sion of, or referral to, basic clinical
services such as voluntary counseling
and testing and diagnosis and treat-
ment of sexually transmitted infections
will be essential.
In addition, site development should
include building skills that are ancillary
but critical to the actual conduct of
clinical trials, such as educating com-
munities, building community part-
nerships, managing site ﬁnances, and
piloting applications through regula-
tory decision-making processes.
Regulatory considerations. The En-
terprise must address a number of
problems that currently impact the
review of HIV vaccine trial protocols
and that could delay future decisions
regarding product licensure in devel-
oping countries. Most regulatory chal-
lenges arise from the fact that
regulatory approvals are granted at the
national level, but many developing
countries lack the expertise, well-de-
ﬁned processes, clear delineation of
authority, and/or other system compo-
nents needed to make regulatory deci-
sions expeditiously. As a result, new
products are often licensed in these
regions based on prior approval in the
US or Europe and/or endorsement by
the WHO. Under these circumstances,
data speciﬁc to developing country
populations (e.g., disease burden or
childhood vaccination schedules) often
do not enter into the decision making.
The absence of deﬁned pathways to
approve products targeting a country’s
needs when a product is not also
submitted to regulators in the US or
Europe remains another obstacle. The
Enterprise process has identiﬁed these
action-item priorities: (1) harmonize
and exchange information needed by
regulatory bodies within the differing
legal frameworks of different countries,
(2) facilitate regulatory decision mak-
ing, possibly using regional approaches
for conducting reviews and making
recommendations, (3) build regulatory
DOI: 10.1371/journal.pmed.0020025.g003
Figure 3. Estimated Adult and Child Deaths from AIDS during 2004 (Total: 3.1 [2.8–3.5] million)
(Map: UNAIDS/WHO)
The acute shortage of
qualified personnel is a
major bottleneck to the
conduct of clinical trials
in developing countries.
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uations in the context of differing
epidemic dynamics and country needs
and resources, (5) identify and remove
potential scientiﬁc impediments to
rapid regulatory decision making, and
(6) address ethical issues that interface
with regulatory decision making, such
as ensuring informed consent and
deﬁning the degree to which trial
participants should receive a standard
of care that is higher than others in
their community.
Intellectual property issues. Given
the Enterprise focus on stronger col-
laboration, data sharing, and use of
common materials and reagents, an
intellectual property (IP) framework
that facilitates this ‘‘enabling environ-
ment’’ is crucial for success. While IP
issues may arise throughout the vaccine
development process, at present the
top priority is to stimulate early stage
research and vaccine design by in-
creasing scientiﬁc freedom to operate
and sharing of data and biological
materials.
Speciﬁc areas for further consider-
ation include: (1) minimizing restric-
tions on freedom of operation, perhaps
by early stage covenants not to litigate
and followed by later stage agreements
based on true valuations of IP; (2)
sharing of information (including clin-
ical trial data), materials, expertise,
trade secrets, and platform technolo-
gies in a protected and secure manner
while also remaining in compliance
with national laws devised to prevent
monopolies and insider trading; (3)
recognizing the contribution of differ-
ent countries to HIV vaccine develop-
ment through approaches that assure
affordable access to successful vaccines;
and (4) maximizing access to essential
technologies and inventions.
Scientific Plan
Scientiﬁc activities. On October 21,
2004, a group of participants from 16
countries, the European Commission,
UNAIDS, and the WHO met to ﬁnalize
the scientiﬁc plan and to discuss how to
formulate speciﬁc actions.
Participants noted that the structure
of an activity should depend on several
factors, including, for example, the
degree to which the activity can be
predeﬁned, the degree to which the
creativity of academic researchers
needs to be harnessed, and the mech-
anisms available to the funding organ-
ization.
A number of options were discussed,
with consensus as to those that would
ﬁt various scientiﬁc priorities.
First, networks of focused consortia
and real or virtual centers are well
suited to systematically address many
of the major scientiﬁc roadblocks
identiﬁed in this plan. These consortia
or centers would link to each other to
ensure a comprehensive, systematic
approach, sharing information so that
each can be as productive as possible,
and also to share reagents and proce-
dures so that data among groups can be
compared and, where possible, merged
for analysis (Figure 4). The speciﬁc
scientiﬁc areas that could be supported
by consortia or centers include (1)
addressing fundamental scientiﬁc
problems, such as the deﬁnition of
correlates of immune protection in
selected animal models and the char-
acterization of acute/early infection in
potential vaccine trial sites; (2) design-
ing and evaluating novel vaccines, such
as immunogens that neutralize primary
isolates, and improved T cell vaccines
that avoid immunological escape and/
or that induce persisting mucosal or
persisting systemic responses; and (3)
providing for a systematic evaluation of
potential adjuvants. The success of
consortia or virtual centers will depend
on engaging the best researchers, get-
ting them to work collaboratively and
dedicate the majority of their effort to
HIV vaccine research, resolving IP
issues, obtaining support for research-
ers from their institutions, and keeping
the group focused on speciﬁc, well-
deﬁned questions. More than one con-
sortium may be needed for systematic
coverage of vaccine design research
(e.g., monoclonal-antibody-identiﬁed
DOI: 10.1371/journal.pmed.0020025.g004
Figure 4. A Possible Model to Address Key Scientific Questions through an Appropriate Organizational Infrastructure
(Courtesy of John Mascola; illustration: Giovanni Maki)
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ﬁed envelope).
Second, a global system of central
laboratories linked to satellite labora-
tories that work together (using GLP)
would provide a range of standardized
functions, help ensure the quality of
clinical research, and enable compar-
ison of data from different trials
(Figure 5). Together this system could
(1) conduct preclinical or clinical as-
says, particularly critical endpoint as-
says that require standardization and/
or validation; (2) develop, optimize, and
validate new assays and platforms; (3)
transfer assays from central labs to
satellite labs; (4) develop and imple-
ment a global quality control/quality
assurance program and proﬁciency
testing for assays performed at central
and satellite laboratories; (5) imple-
ment vaccine-related research that re-
quires validated assays and close
cooperation and collaboration among
labs globally, such as a Virus Neutral-
ization Serotype Discovery Program,
and the characterization of recently
transmitted HIV isolates; and (6) con-
tribute to the development of techno-
logical infrastructure in developing
countries.
Third, a number of contract labora-
tories capable of developing, acquiring,
storing, and distributing common re-
agents will prove critical to the success
of collaborative research and develop-
ment projects, and to ensuring reagent
quality. These reagents could include
(1) peptides, antisera/antibodies, and
viral isolates for immune assays, in-
cluding a standard panel of virus
strains and sera representative of the
global genetic and immunologic varia-
bility of HIV, and (2) additional broadly
neutralizing monoclonal antibodies,
especially from non-clade B viruses, to
facilitate elucidation of the motif or
motifs they recognize. These contract
laboratories would be expected to work
very closely with and enable the work
of Enterprise consortia, centers, im-
mune assessment laboratories, and
clinical sites.
Fourth, a network of Clinical Re-
search Training Centers in developing
countries could work collaboratively to
ensure development of quality trial
sites. These centers would (1) conduct
or facilitate training of trial site per-
sonnel in activities that are generic to
the conduct of clinical trials, as well as
those speciﬁc for HIV vaccine trials, for
example, an HIV vaccine fellowship
program for developing country scien-
tists; (2) coordinate and work together
with other Enterprise consortia or
centers, such as those established to
characterize acute/early infection in
developing country settings or to pre-
pare a standard panel of HIV strains
representative of currently circulating
viruses; and (3) share standard operat-
ing procedures, vaccine development
plans, and strategies for engaging and
ensuring community and political sup-
port.
Fifth, a network of individuals and
companies with manufacturing experi-
ence, particularly process development
expertise, could link to consortia, cen-
ters, and others involved in vaccine
development to provide development
and manufacturing expertise to facili-
tate the advancement of improved HIV
vaccine candidates.
The above structures are proposed to
address the initial Enterprise scientiﬁc
priorities. Additional consultative
groups, reference and centralized fa-
cilities, and other mechanisms may be
needed to facilitate collaborative work
and strengthen the global capacity for
the conduct of HIV vaccine research
and development as the ﬁeld pro-
gresses.
Different implementing and funding
DOI: 10.1371/journal.pmed.0020025.g005
Figure 5. A Possible Model for a Comprehensive Global Laboratory Network for the Standardized
Assessment of Humoral Immune Responses
(Courtesy of David Monteﬁori; illustration: Giovanni Maki)
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collaboration to ensure harmonious
implementation of the scientiﬁc plan.
Initial actions should focus on the areas
of vaccine discovery and standardiza-
tion of laboratory assays, which are
considered critical for the success of
the Enterprise and the eventual devel-
opment of a safe and effective HIV
vaccine. Activities to address recom-
mendations in the areas of product
development and manufacturing, clin-
ical trials capacity, regulatory consid-
erations, and IP issues should
be launched after these initial
components of the plan are
under way.
Regardless of timing, each
scientiﬁc endeavor needs to
outline speciﬁc strategies to
ensure information exchange
and capacity building among
the collaborating partners
and institutions. The funding
mechanisms employed (i.e.,
contracts, grants, interagency
agreements, etc.) will depend
on the task to be accom-
plished and the needs and
capabilities of each funding
organization. In the spirit of
coordination, collaboration,
and transparency promoted
by the Enterprise, two or
more partners may jointly
support one or more activ-
ities, taking care to avoid
duplication in the use of their
respective resources. When a
research area is jointly
funded, all communication
regarding goals, research
plans, progress, obstacles, etc.,
should be openly and trans-
parently shared among all
stakeholders—funders, proj-
ect managers, and researchers.
Guiding principles. As an alliance of
independent entities, the Global HIV/
AIDS Vaccine Enterprise will be chal-
lenged to carry out three essential
functions. One is to continue regular
scientiﬁc assessments. The scientiﬁc
priorities outlined in this paper will
need to be monitored, re-evaluated,
and updated. An evolving scientiﬁc
plan must reﬂect lessons learned, new
opportunities, and the inﬂuence of new
scientiﬁc ﬁndings and new technolo-
gies. Revised versions of the scientiﬁc
plan must be made fully and publicly
available. The second essential function
is to establish global processes. To
optimize progress across a large and
complex set of activities at the global
level, standards, performance criteria,
and processes for data sharing, com-
munication, and convening must be
established. The Enterprise will con-
vene fora to address policy issues such
IP, clinical trials, site development, and
regulatory hurdles. And the third es-
sential function is shared accountabil-
ity. The partners in this alliance will
need to create a culture of mutual
accountability for the effective imple-
mentation of the scientiﬁc strategic
plan. Since the Enterprise is not a
single organization, a shared ‘‘way of
doing business’’ is one of its most
important deﬁning traits. Articulating
an explicit set of ‘‘working principles’’
is therefore crucial to the identity and
smooth functioning of the Enterprise.
For the Enterprise as a whole the
following conditions apply: (1) the
central task is to develop and imple-
ment an ambitious scientiﬁc plan with
the necessary scale, balance and se-
quence of activities, and structure to
carry it out; (2) the plan must focus on
critical roadblocks that would beneﬁt
substantially from global collaboration
while fostering continued R&D by
individuals, small groups, and individ-
ual networks; (3) the incentives holding
the alliance together will include col-
laborative arrangements and structures
that give people the resources, neces-
sary critical mass, centralized facilities,
common reagents, assays and technol-
ogies, and data they need to effectively
remove critical roadblocks; (4) all
activities will reﬂect the commit-
ment to create an environment
that maximizes the ability of
participants to share data and
biological materials, e.g., through
the use of common standards for
measurements and appropriate IP
arrangements; and (5) the Enter-
prise also commits to working for
rapid global access to a successful
vaccine.
For participating investigators
and organizations, key principles
include (1) the willingness and
desire to work in an open, col-
laborative fashion, sharing data
and reagents in a collegial fashion,
with the appropriate balance be-
tween productive competition
and effective collaboration, and
(2) the willingness and ability to
devote the majority of their time
to tackling these problems within
a focused environment, com-
pletely committing to solve the
problems at hand.
Organizational structure of the
Enterprise. The implementation
of the scientiﬁc plan of the Enter-
prise will be overseen and sup-
ported by the organizational
structure described in Figure 6.
The Coordinating Committee will
facilitate all aspects of the Enterprise’s
activities. This committee consists of
representatives of the Enterprise
founders as well as additional scientiﬁc
leaders selected from inside and out-
side the ﬁeld of HIV vaccine research
and development. The committee will
develop procedures for term rotation
and inclusion of new members, to
ensure appropriate representation of
all relevant partners, and will engage
external stakeholders for advice, ex-
pertise, and assistance, appointing
technical expert groups as needed. A
Secretariat will provide logistical and
DOI: 10.1371/journal.pmed.0020025.g006
Figure 6. Proposed Organizational Structure of the Global HIV/
AIDS Vaccine Enterprise (Illustration: Giovanni Maki)
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nating Committee and Enterprise
partners. The BMGF will serve as
Interim Secretariat until a permanent
Secretariat is established.
The Funders Forum will be an open
forum of sovereign, independent
funding organizations, starting with a
nucleus of those who already embrace
the principles of the Enterprise and
who are actively supporting or intend
to support and fund HIV vaccine
research and development. Members of
the Funders Forum will be high-level
decision makers within the ranks of
funding organizations and govern-
ments, as close as possible to the source
of resources. Since the Enterprise is not
a discrete organization with a pool of
money, funders will support speciﬁc
areas using their own mechanisms,
according to their own practices and
policies, and following Enterprise
principles. The scientiﬁc plan will
provide guidance that may help fun-
ders better align existing resources but,
more importantly, will facilitate the
efﬁcient and focused application of
new resources as they become available.
Multiple funders who wish to support a
single Enterprise-deﬁned project could
form collaborative agreements, memo-
randa of understanding, or other forms
of written agreement among them-
selves to outline their respective roles
and responsibilities; address IP, pro-
gram management, oversight, and oth-
er issues; and establish mechanisms for
communication and conﬂict resolu-
tion. The funders with greatest ﬂexi-
bility could provide incentives for
sharing reagents and data, and linking
projects together, e.g., by supporting
the additional work that nationally or
regionally funded laboratories would
need to undertake in order to partic-
ipate in a global network, or by
supporting a program to develop and
share reagents.
In some cases, funders may wish to
support an implementing organization
that will take responsibility for manag-
ing the project and reporting back to
the funder and other stakeholders. In
other cases, funders may have the
capability and capacity to play a sub-
stantial role in facilitating the project.
In still other cases, funders may have
the capability to assume a leadership
role in overseeing the conduct of the
activity, particularly in cases where the
activity is well deﬁned in advance.
In addition, an Annual Stakeholders
Forum will be organized to bring
together the broader community of
scientists, policy makers, public health
ofﬁcials, and community representa-
tives involved in the search for an HIV/
AIDS vaccine. This meeting will serve
as a forum to (1) update the broader
community on Enterprise activities and
progress, and (2) provide the com-
munity with a mechanism for feedback
and dialog.
Funding issues. Global expenditures
on HIV vaccine research and develop-
ment in 2002 were tentatively esti-
mated to be on the order of US$624–
670 million, the large majority (67.3%)
provided by the public sector, followed
by the philanthropic sector (17.4%)
and industry (15.3%). An analysis of
how those funds have been invested
revealed that the large majority (43.1%)
is being used in preclinical research
activities, followed by clinical trials
(28.2%), basic research (20.7%), cohort
development and clinical trial infra-
structure (6.5%), and vaccine educa-
tion, advocacy, and policy development
(1.4%) [27].
The largest funder of HIV vaccine
research and development activities
has been the NIH, with almost US$350
million in 2002. The NIH budget for
HIV vaccine research has grown from
less than US$50 million in 1996, to an
estimated US$514.6 million for 2005,
corresponding to 17.6% of the NIH
total HIV-related research budget for
2005.
The Enterprise Coordinating Com-
mittee will analyze the additional ﬁ-
nancial requirements to fully
implement the scientiﬁc plan of the
Enterprise, and the Enterprise Secre-
tariat will explore options to leverage
these funds from the public and private
sector. Initial estimates by Enterprise
partners suggest that US$1.2 billion per
year, or double the current expendi-
tures on HIV vaccine research and
development, will be needed. Although
this amount may appear unrealistic at
present, it would represent only a
fraction of the total global expendi-
tures in response to the AIDS pan-
demic and a very reasonable
investment in view of the enormous
social, political, and economic conse-
quences of the pandemic. However, it is
essential that the proposed increase in
funding for HIV vaccine R&D be addi-
tional to existing AIDS expenditures,
and not at the expense of current
prevention, treatment, and care efforts.
The founding partners of the Enter-
prise, including the NIH, the BMGF,
and the Wellcome Trust have already
committed, or are considering com-
mitting, resources towards new initia-
tives that will begin to enact portions of
the Enterprise scientiﬁc plan over the
next six to nine months. Each funder
will utilize their own funding processes
and will align the design, scope, and
scale of programs to those laid out in
this plan. For example, the NIH Na-
tional Institute of Allergy and Infec-
tious Diseases will establish the Center
for HIV Vaccine Immunology, which
will target several scientiﬁc priorities
identiﬁed here.
Political support. As a sign of global
recognition of the importance of bet-
ter, more strategic coordination in the
search for an HIV vaccine, the ‘‘Group
of Eight’’ leading industrialized nations
in June 2004 endorsed the goals of the
Enterprise and agreed to review pro-
gress in implementation at its 2005
summit meeting in the United King-
dom [28]. Likewise, on October 19,
2004, Ministers of Health from seven
European countries (France, Germany,
Italy, the Netherlands, Spain, Sweden,
and the United Kingdom) adopted a
statement of intent to coordinate ef-
forts to accelerate research for an HIV
vaccine within the context of the global
effort.
Next Steps
With almost 5 million new HIV
infections and 3 million AIDS deaths
occurring every year worldwide, the
development of a safe, effective, and
accessible HIV vaccine represents one
of the most urgent global public health
needs. This global emergency led to the
proposal to harness the power of
science to ﬁnd a deﬁnitive solution to
one of the most catastrophic health
problems of our time. The Global HIV/
AIDS Vaccine Enterprise has evolved
over the past 18 months from a concept
proposed in a scientiﬁc journal by a
cadre of researchers to a global con-
sensus concerning the major scientiﬁc
roadblocks facing HIV vaccine devel-
The road to success will
be a bumpy one.
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dress those roadblocks, and guiding
principles for the plan’s implementa-
tion in a manner and degree commen-
surate with the challenges at hand.
Several organizations have already em-
braced the Enterprise concept and are
moving to tackle portions of the sci-
entiﬁc plan. Still, much more remains
to be done. The road to success will be
a bumpy one requiring the energy,
commitment, and action of a wide
number of government and non-gov-
ernmental organizations globally. Rec-
ognizing the enormity of the
roadblocks as well as the potential
beneﬁts of a safe and effective HIV
vaccine, it is essential that many more
organizations and agencies contribute
additional expertise and resources and
work together as a global community in
a cooperative, collaborative, and
transparent manner to fully implement
the Enterprise scientiﬁc plan. &
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